Primary Idiopathic Pseudopelade of Brocq: Five Case Reports

    NilofarG Diwan, NilofarG Diwan, Pragya A Nair
    TLDR Primary idiopathic pseudopelade of Brocq causes gradual, scarring hair loss with no effective treatment.
    The document reported on five cases of primary idiopathic pseudopelade of Brocq (PPB), a rare and self-limiting hair disorder leading to progressive cicatricial alopecia. The patients, aged 29 to 45, exhibited asymptomatic, gradual hair loss with no inflammation or trauma history. Histopathology confirmed follicular scarring without other changes, supporting the diagnosis of primary idiopathic PPB. Despite treatment with intralesional triamcinolone acetonide, no significant response was observed. The study highlighted the lack of standard treatment for PPB and the need for further research into its pathogenesis and management.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 289 results

      community Rare Non responder to Finasteride, Dutasteride, and oral minoxidil

      in Minoxidil  78 upvotes 9 months ago
      A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

      community DHT levels after 4 weeks of Fina and 8 weeks of Fina + 4 weeks of Duta

      in Update  35 upvotes 5 years ago
      The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  119 upvotes 6 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    2 / 2 results